vs
Side-by-side financial comparison of BALCHEM CORP (BCPC) and Eastern Bankshares, Inc. (EBC). Click either name above to swap in a different company.
Eastern Bankshares, Inc. is the larger business by last-quarter revenue ($295.9M vs $263.6M, roughly 1.1× BALCHEM CORP). Eastern Bankshares, Inc. runs the higher net margin — 22.1% vs 14.9%, a 7.2% gap on every dollar of revenue. On growth, BALCHEM CORP posted the faster year-over-year revenue change (9.8% vs 1.7%). Over the past eight quarters, Eastern Bankshares, Inc.'s revenue compounded faster (38.6% CAGR vs 4.9%).
Balchem Corp is a global specialty chemicals and nutritional ingredients provider that develops, manufactures and distributes application-specific products for human nutrition, animal health, pharmaceutical and industrial end markets, serving customers across North America, Europe and Asia Pacific.
Eastern Bank is a bank based in Boston, Massachusetts. Before de-mutualizing in 2020, it was the oldest and largest mutual bank in the United States and the largest community bank in Massachusetts.
BCPC vs EBC — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $263.6M | $295.9M |
| Net Profit | $39.2M | $65.3M |
| Gross Margin | 35.6% | — |
| Operating Margin | 19.8% | — |
| Net Margin | 14.9% | 22.1% |
| Revenue YoY | 9.8% | 1.7% |
| Net Profit YoY | 16.8% | 289.8% |
| EPS (diluted) | $1.21 | $0.29 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $295.9M | ||
| Q4 25 | $263.6M | $37.5M | ||
| Q3 25 | $267.6M | $241.5M | ||
| Q2 25 | $255.5M | $244.9M | ||
| Q1 25 | $250.5M | $31.1M | ||
| Q4 24 | $240.0M | $216.5M | ||
| Q3 24 | $239.9M | $203.4M | ||
| Q2 24 | $234.1M | $154.0M |
| Q1 26 | — | $65.3M | ||
| Q4 25 | $39.2M | $99.5M | ||
| Q3 25 | $40.3M | $106.1M | ||
| Q2 25 | $38.3M | $100.2M | ||
| Q1 25 | $37.1M | $-217.7M | ||
| Q4 24 | $33.6M | $60.8M | ||
| Q3 24 | $33.8M | $-6.2M | ||
| Q2 24 | $32.1M | $26.3M |
| Q1 26 | — | — | ||
| Q4 25 | 35.6% | — | ||
| Q3 25 | 35.7% | — | ||
| Q2 25 | 36.4% | — | ||
| Q1 25 | 35.2% | — | ||
| Q4 24 | 36.0% | — | ||
| Q3 24 | 35.6% | — | ||
| Q2 24 | 35.5% | — |
| Q1 26 | — | — | ||
| Q4 25 | 19.8% | — | ||
| Q3 25 | 20.4% | 38.9% | ||
| Q2 25 | 20.1% | 41.0% | ||
| Q1 25 | 20.4% | -590.9% | ||
| Q4 24 | 19.8% | 33.3% | ||
| Q3 24 | 20.0% | -1.6% | ||
| Q2 24 | 19.6% | 24.7% |
| Q1 26 | — | 22.1% | ||
| Q4 25 | 14.9% | 265.6% | ||
| Q3 25 | 15.1% | 44.0% | ||
| Q2 25 | 15.0% | 40.9% | ||
| Q1 25 | 14.8% | -699.2% | ||
| Q4 24 | 14.0% | 28.1% | ||
| Q3 24 | 14.1% | -3.0% | ||
| Q2 24 | 13.7% | 17.1% |
| Q1 26 | — | $0.29 | ||
| Q4 25 | $1.21 | $0.48 | ||
| Q3 25 | $1.24 | $0.53 | ||
| Q2 25 | $1.17 | $0.50 | ||
| Q1 25 | $1.13 | $-1.08 | ||
| Q4 24 | $1.03 | $0.29 | ||
| Q3 24 | $1.03 | $-0.03 | ||
| Q2 24 | $0.98 | $0.16 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $74.6M | $551.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.3B | $4.3B |
| Total Assets | $1.7B | $30.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $551.7M | ||
| Q4 25 | $74.6M | $507.6M | ||
| Q3 25 | $65.1M | $703.4M | ||
| Q2 25 | $65.4M | $948.3M | ||
| Q1 25 | $49.9M | $609.0M | ||
| Q4 24 | $49.5M | $1.9B | ||
| Q3 24 | $73.7M | $1.7B | ||
| Q2 24 | $63.7M | $1.4B |
| Q1 26 | — | $4.3B | ||
| Q4 25 | $1.3B | $4.3B | ||
| Q3 25 | $1.3B | $3.8B | ||
| Q2 25 | $1.3B | $3.7B | ||
| Q1 25 | $1.2B | $3.6B | ||
| Q4 24 | $1.1B | $3.6B | ||
| Q3 24 | $1.2B | $3.7B | ||
| Q2 24 | $1.1B | $3.0B |
| Q1 26 | — | $30.6B | ||
| Q4 25 | $1.7B | $30.6B | ||
| Q3 25 | $1.7B | $25.5B | ||
| Q2 25 | $1.7B | $25.5B | ||
| Q1 25 | $1.6B | $25.0B | ||
| Q4 24 | $1.6B | $25.6B | ||
| Q3 24 | $1.6B | $25.5B | ||
| Q2 24 | $1.6B | $21.0B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $67.3M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 1.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $67.3M | $432.4M | ||
| Q3 25 | $65.6M | $157.1M | ||
| Q2 25 | $47.3M | $123.9M | ||
| Q1 25 | $36.5M | $47.3M | ||
| Q4 24 | $52.3M | $283.8M | ||
| Q3 24 | $51.3M | $108.3M | ||
| Q2 24 | $45.0M | $54.3M |
| Q1 26 | — | — | ||
| Q4 25 | 1.72× | 4.35× | ||
| Q3 25 | 1.63× | 1.48× | ||
| Q2 25 | 1.23× | 1.24× | ||
| Q1 25 | 0.98× | — | ||
| Q4 24 | 1.56× | 4.67× | ||
| Q3 24 | 1.52× | — | ||
| Q2 24 | 1.40× | 2.06× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BCPC
| Human Nutrition And Health | $166.1M | 63% |
| Animal Nutrition And Health | $61.2M | 23% |
| Specialty Products | $34.8M | 13% |
EBC
| ALLL / total nonperforming loans ("NPLs") | $238.2M | 80% |
| Other | $51.6M | 17% |
| Return on average shareholders' equity | $6.1M | 2% |
